Announcements Trials
Browse Landscape

Phase

Phase 1 46Phase 2 37Phase 1/2 24Phase 3 6Phase EARLY_PHASE1 3Phase 2/3 3Phase NA 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 1

Conditions

Recurrence 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Lymphoma, T-Cell 1Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Decitabine × Clear all
NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Completed
22 enrolled
Lymphoid

Lymphoma, Neoplasms, Recurrence

NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
13 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02846935 2019-01-07

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
7 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡